Search

Your search keyword '"de Vries, E. G. E"' showing total 279 results
Start Over Author "de Vries, E. G. E" Search Limiters Full Text
279 results on '"de Vries, E. G. E"'

2. One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

Author

van der Veldt, A A M, Oosting, S F, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, Hartog, G den, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Ernst, S M, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G, de Vries, E G E, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Translational Immunology Groningen (TRIGR), Targeted Gynaecologic Oncology (TARGON), Medical Oncology, Radiology & Nuclear Medicine, Virology, and Pulmonary Medicine

Subjects
Cancer Research, Oncology, SDG 3 - Good Health and Well-being
Published
2023

5. 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

Author

Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Kok, I C, Hooiveld, J S, van de Donk, P P, Giesen, D, van der Veen, E L, Lub-de Hooge, M N, Brouwers, A H, Hiltermann, T J N, van der Wekken, A J, Hijmering-Kappelle, L B M, Timens, W, Elias, S G, Hospers, G A P, Groen, H J M, Uyterlinde, W, van der Hiel, B, Haanen, J B, de Groot, D J A, Jalving, M, de Vries, E G E, Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Kok, I C, Hooiveld, J S, van de Donk, P P, Giesen, D, van der Veen, E L, Lub-de Hooge, M N, Brouwers, A H, Hiltermann, T J N, van der Wekken, A J, Hijmering-Kappelle, L B M, Timens, W, Elias, S G, Hospers, G A P, Groen, H J M, Uyterlinde, W, van der Hiel, B, Haanen, J B, de Groot, D J A, Jalving, M, and de Vries, E G E

Published
2022

9. Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally

Author

Latino, N J, Galotti, M, Cherny, N I, de Vries, E G E, Douillard, J-Y, Kaidarova, D, Ilbawi, A, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Cancer Research, China, Oncology, Neoplasms, Humans, Immunotherapy, Medical Oncology
Abstract

BACKGROUND: In Kazakhstan, cancer is the second leading cause of death with a major public health and economic burden. In the last decade, cancer care and cancer medicine costs have significantly increased. To improve the efficiency and efficacy of cancer care expenditure and planning, the Kazakhstan Ministry of Health requested assistance from the World Health Organization (WHO) and the European Society for Medical Oncology (ESMO) to review its systemic cancer treatment protocols and essential medicines list and identify high-impact, effective regimens.MATERIALS AND METHODS: ESMO developed a four-phase approach to review Kazakhstan cancer treatment protocols: (i) perform a systematic analysis of the country's cancer medicines and treatment protocols; (ii) cross-reference the country's cancer protocols with the WHO Model List of Essential Medicines, the ESMO-Magnitude of Clinical Benefit Scale and the European Medicines Agency's medicine availability and indications database; (iii) extract treatment recommendations from the ESMO Clinical Practice Guidelines; (iv) expert review for all cancer medicines not on the WHO Model List of Essential Medicines and the country treatment protocols.RESULTS: This ESMO four-phase approach led to the update of the Kazakhstan national essential cancer medicines list and the list of cancer treatment protocols. This review has led to the withdrawal of several low-value or non-evidence-based medicines and a budget increase for cancer care to include all essential and highly effective medicines and treatment options.CONCLUSION: When applied effectively, this four-phase approach can improve access to medicines, efficiency of expenditure and sustainability of cancer systems. The WHO-ESMO collaboration illustrated how, by sharing best practices, tools and resources, we can address access to cancer medicines and positively impact patient care.

Published
2022

11. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Author

Gebhart, G., Lamberts, L. E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., Oyen, W. J. G., Vugts, D. J., Hoekstra, O. S., Schröder, C. P., Menke-van der Houven van Oordt, C. W., Guiot, T., Brouwers, A. H., Awada, A., de Vries, E. G. E., and Flamen, P.

Published
2016
Full Text
View/download PDF

19. [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Author

van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S, Menke-van der Houven van Oordt, C W, van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S, and Menke-van der Houven van Oordt, C W

Published
2020

20. [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Author

Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S, Menke-van der Houven van Oordt, C W, Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S, and Menke-van der Houven van Oordt, C W

Published
2020

23. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Author

Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H., Cornelissen, S., Holtkamp, M., Froklage, F. E., de Vries, E. G. E., Schrama, J. G., Wesseling, J., van de Vijver, M. J., van Tinteren, H., de Bruin, M., Hauptmann, M., Rodenhuis, S., and Linn, S. C.

Published
2011
Full Text
View/download PDF

44. Zirconium-89 (89Zr)-labeled bispecific T-cell engager (BiTE (R)) AMG 211 PET imaging to determine AMG 211 biodistribution in patients with gastrointestinal (GI) adenocarcinomas

Author

Moek, K. L., Waaijer, S. J. H., Kok, I.C., Suurs, F. V., Brouwers, A., van Oordt, C. W. Menke-van der Houven, Wind, T. T., Gietema, J. A., Schröder, C. P., Mahesh, S. V. K., Jorritsma-Smit, A., Hooge, M. N. Lub-De, Fehrmann, R. S. N., de Groot, D. J., de Vries, E. G. E., Guided Treatment in Optimal Selected Cancer Patients (GUTS), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Published
2018

48. Other Radiopharmaceuticals for Imaging GEP-NET

Author

Koopmans, K P, Dierckx, Rudi, Elsinga, Philip H., Links, Thera, Kema, Ido, Fiebrich, Helle Brit, Walekamp, A M E, de Vries, E. G. E., Brouwers, Adrienne, Hubalewska‐Dydejczyk, Alicja, Signore, Alberto, de Jong, Marion, Dierckx, Rudi A., Buscombe, John, Van de Wiele, Christophe, Molecular Neuroscience and Ageing Research (MOLAR), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Lifestyle Medicine (LM), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Subjects
medicine.medical_specialty, education.field_of_study, business.industry, Population, medicine.disease, Serotonin pathway, Functional imaging, Endocrinology, Somatostatin, Internal medicine, Radionuclide therapy, medicine, Cancer research, Catecholamine, business, education, Receptor, Progressive disease, medicine.drug
Abstract

In GEP‐NETs, especially the catecholamine and serotonin biosynthetic pathways are upregulated. Therefore, increased biosynthesis of these specific amines in GEP‐NETs enables imaging with specific amine precursors. For the catecholamine pathway, 6‐18F ‐l‐3,4‐dihydroxyphenylalanine (18F‐DOPA) is available, while for the serotonin pathway, carbon‐11‐labeled 5‐hydroxy‐l‐tryptophan ([11C]‐5‐HTP) is available as tracer. 11C‐5‐HTP PET and 18F‐DOPA PET are excellent functional imaging techniques for evaluating patients with proven pancreatic islet cell tumors and carcinoids. For both tracers, the combination with CT further improves the detection rate of NET, which shows that performing PET scans with these tracers in PET/CT scanners is beneficial for patients.Since well‐differentiated GEP‐NETs generally have a low glucose metabolism, 18F‐fluorodexyglucose (18F‐FDG) PET scanning has limited value for the primary staging of patients with well‐differentiated GEP‐NETs. However, in patients with rapidly progressive disease, dedifferentiation of GEP‐NET tumors can lead to a higher glucose metabolism in tumor cells. In these patients, 18F‐FDG PET can be of benefit for tumor staging. Also, 18F‐FDG PET can be of value when other malignancies are suspected in patients with GEP‐NETs, since these patients experience a higher incidence of these malignancies compared to the general population.Nowadays, (GEP)‐NETs can also be imaged with 68Ga‐labeled analogues of somatostatin, which are also PET tracers. Advantages of 68Ga‐labeled somatostatin analogues are the relatively easy generator‐based synthesis and the possibility to evaluate whether peptide (somatostatin) receptor radionuclide therapy (PRRT) for NETs can be considered.

Published
2015

49. Microenvironment involved in FPR1 expression by human glioblastomas

Author

Boer, J. C., van Marion, D. M S, Joseph, J. V., Kliphuis, N. M., Timmer-Bosscha, H., van Strijp, J. A G, de Vries, E. G E, den Dunnen, W. F A, Kruyt, F. A E, Walenkamp, A. M E, Boer, J. C., van Marion, D. M S, Joseph, J. V., Kliphuis, N. M., Timmer-Bosscha, H., van Strijp, J. A G, de Vries, E. G E, den Dunnen, W. F A, Kruyt, F. A E, and Walenkamp, A. M E

Published
2015

50. Microenvironment involved in FPR1 expression by human glioblastomas

Author

MMB Research line 1, Infection & Immunity, Boer, J. C., van Marion, D. M S, Joseph, J. V., Kliphuis, N. M., Timmer-Bosscha, H., van Strijp, J. A G, de Vries, E. G E, den Dunnen, W. F A, Kruyt, F. A E, Walenkamp, A. M E, MMB Research line 1, Infection & Immunity, Boer, J. C., van Marion, D. M S, Joseph, J. V., Kliphuis, N. M., Timmer-Bosscha, H., van Strijp, J. A G, de Vries, E. G E, den Dunnen, W. F A, Kruyt, F. A E, and Walenkamp, A. M E

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results